Wigal T, et al. - Physicians aimed to determine the efficacy, safety, tolerability, and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with attention-deficit/hyperactivity disorder (ADHD). With an effect size of 1.09, mazindol CR was efficacious in the treatment of adults with ADHD. It was well-tolerated, with no discontinuations in the mazindol CR group related to treatment. Findings justified progression to phase three studies.